Results 171 to 180 of about 97,795 (300)

Limitations of PIV Biomarker Analysis Related to Chemoradiotherapy and Unadjusted Confounders. [PDF]

open access: yesCancer Sci
The pan‐immune‐inflammation value (PIV) derived from four blood cell counts warrants cautious interpretation in rectal‐cancer immunotherapy, as CRT cannot be disentangled from anti‐PD‐1 effects within the small n = 16 subgroup.
Gao H, Weng W.
europepmc   +2 more sources

Dosimetric risk factors for therapy‐related pneumonitis in patients with immunotherapy plus chemotherapy concurrent thoracic radiotherapy

open access: yesPrecision Radiation Oncology, EarlyView.
In this study, mean lung dose (MLD) and age were associated with an increased risk of treatment‐related pneumonitis in patients receiving concurrent chemoradiotherapy and immunotherapy, providing a reference for revising lung dose constraints. Abstract Objective Combining immune checkpoint inhibitors (ICIs) with chemoradiotherapy is being actively ...
Ying Lu   +9 more
wiley   +1 more source

Regulating Lipid Metabolism in Cancer: The Therapeutic Potential of Traditional Chinese Medicine

open access: yesPhytotherapy Research, EarlyView.
By regulating the reprogramming of lipid metabolism in tumor cells, TCM provides a novel strategy for antitumor therapy with reduced toxicity and enhanced efficacy. ABSTRACT Lipid metabolic reprogramming is a key feature of tumor cells to adapt to the microenvironment and plays an important role in tumor growth, invasion, and metastasis.
Yufeng Gao   +11 more
wiley   +1 more source

Outcomes in Orbit‐Sparing Versus Orbit‐Sacrificing Surgery for Sinonasal Malignancies With Orbital Involvement: A Systematic Review and Meta‐Analysis

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Background Sinonasal malignancies with orbital involvement may be managed with orbit‐sacrificing or orbit‐preserving surgical approaches, with a recent shift towards orbital preservation to reduce postoperative morbidity while maintaining oncological success.
Claire Jing‐Wen Tan   +9 more
wiley   +1 more source

Biomarkers Predictive of Immunotherapy Efficacy in Head and Neck Squamous Cell Carcinoma: Current Insights and Future Perspectives

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT With the approval of immunotherapies by regulatory bodies, head and neck squamous cell carcinoma (HNSCC) treatment has been revolutionized, and anti‐programmed cell death‐1 (anti‐PD‐1) agents are now the standard for platinum‐resistant recurrent/metastatic HNSCC.
Xiao‐Tong Yan   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy